AIF is the investment and innovation arm for ASD and related conditions.

Meet our portfolio companies >>

September, 2021

SpectrumAI

behavioral intervention is clinically validated and data-driven.

Series C, 2021

microbiome-targeted
therapeutics exist to improve
nervous system function.

Seed, 2021

care for individuals with
disabilities is accessible.

Series A, 2021

therapeutics exist to address
core symptoms of
neurological conditions.

Seed, 2021

therapy for behavioral
conditions is affordable
and tech-enabled.

Bridge, 2021

where chronic health
conditions are manageable
through precision nutrition.

Growth, 2021

employment opportunities
for neurodiverse individuals
are plentiful.


Strategic, 2022

care for neurological
conditions is comprehensive,
outcomes-based, and
led by doctors.

AIF is the investment and innovation arm for ASD and related conditions.

Meet our portfolio companies >>

Cision PRNewswire / May 24, 2022

AIF and Arsenal Capital Partners Form...

Orlando Business Journal / June 28, 2022

AIF Flush with Cash and Looking for Deals...

Latest news

Seed, 2021

diagnosis for neurodevelopmental disorders is achievable with a simple blood test

AIF is building a world where

September, 2021

behavioral therapy is clinically validated and data-driven

SpectrumAI

Series C, 2021

microbiome-targeted therapeutics exist to improve nervous system function

Seed, 2021

care for individuals with disabilities is accessible

Series A, 2021

therapeutics exist to address core symptoms of neurological conditions

Seed, 2021

therapy for behavioral conditions is affordable and tech-enabled

Bridge, 2021

where chronic health conditions are manageable through precision nutrition

Growth, 2021

employment opportunities for neurodiverse individuals are plentiful


Strategic, 2022

care for neurological conditions is comprehensive, outcomes-based, and led by doctors

OUR MISSION

AIF’s bold mission is to revolutionize the status quo for diagnosing, treating, and living with autism spectrum disorder (ASD), neurodevelopmental disorders, mental health issues, and complex chronic conditions through a venture capital model that helps accelerate developing and delivering emerging technologies, translational science, and innovative services to empower individuals to reach their full potential.

OUR VISION

We identify unmet needs across the continuum of ASD and related conditions and deploy venture capital to invent, develop, and fuel solutions that address those needs. 

AS SEEN IN

AS SEEN IN

AS SEEN IN